Dexcom (DXCM) director sells 1,012 shares under 10b5-1 plan

Rhea-AI Filing Summary

Dexcom Inc. director Bridgette P. Heller reported an open-market sale of 1,012 shares of common stock at $60.01 per share. After the transaction, she directly holds 25,007 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, which provides for orderly share dispositions.

Insider Trade Summary 10b5-1

Net Seller: 1,012 shares ($60,730)

Net Sell 1 txn

Insider Heller Bridgette P

Role null

Sold 1,012 shs ($61K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,012	$60.01	$61K

Holdings After Transaction: Common Stock — 25,007 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 1,012 shares Sale price: $60.01 per share Shares owned after sale: 25,007 shares +1 more

4 metrics

Shares sold 1,012 shares Open-market sale of Dexcom common stock

Sale price $60.01 per share Price for the 1,012 shares sold

Shares owned after sale 25,007 shares Direct Dexcom holdings following the transaction

Transaction code S Open-market or private sale of non-derivative securities

Key Terms

Rule 10b5-1 Plan, open-market sale, Form 4, non-derivative

4 terms

Rule 10b5-1 Plan regulatory

"This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Heller."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

""transaction_type": "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heller Bridgette P

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		S		1,012(1)	D	$60.01	25,007	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On August 14, 2025, Ms. Heller adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Heller. The shares set forth above were sold pursuant to the 10b5-1 Plan.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Bridgette P. Heller	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Dexcom (DXCM) report for Bridgette P. Heller?

Dexcom disclosed that director Bridgette P. Heller sold 1,012 shares of common stock. The shares were sold in an open-market transaction at $60.01 per share under a pre-arranged Rule 10b5-1 trading plan.

At what price did the Dexcom (DXCM) director sell her shares?

Bridgette P. Heller sold her 1,012 Dexcom shares at $60.01 each. This was an open-market sale executed under a Rule 10b5-1 trading plan designed to allow orderly, pre-scheduled stock dispositions over time.

How many Dexcom (DXCM) shares does Bridgette P. Heller own after the sale?

Following the reported sale, Bridgette P. Heller directly owns 25,007 Dexcom common shares. This indicates the transaction covered a relatively small portion of her holdings, with the remaining stake disclosed as part of the same Form 4 filing.

Was the Dexcom (DXCM) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing notes Heller adopted a Rule 10b5-1 plan on August 14, 2025. The 1,012 shares reported sold on the Form 4 were disposed of pursuant to this plan, indicating the trades were pre-arranged rather than discretionary.

What type of transaction code was used in the Dexcom (DXCM) Form 4?

The Form 4 lists transaction code “S,” representing a sale in the open market or a private transaction. The trade involved 1,012 Dexcom common shares at $60.01 per share, categorized as a non-derivative transaction with direct ownership.